Send to

Choose Destination
1533-440637382015Aug20The New England journal of medicineN. Engl. J. Med.Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.726-3610.1056/NEJMoa1502309BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers.We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival.In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma.BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; number, NCT01524978.).HymanDavid MDMFrom Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut Bergonié Cancer Center, Bordeaux (A.I.) - all in France; University Hospital of Cologne, Cologne (J.W.), Universitätsmedizin Mannheim, Mannheim (R.-D.H.), West German Cancer Center, University Hospital Essen, Essen (M.S.), and German Cancer Consortium, Heidelberg (M.S.) - all in Germany; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona (M.E.E.-F., J.T.), and Hospital Universitario Madrid Sanchinarro, Madrid (M.H.) - both in Spain; and F. Hoffmann-La Roche, Basel, Switzerland (S.F.L., M.M., F.S., M.L.V.).PuzanovIgorISubbiahVivekVFarisJason EJEChauIanIBlayJean-YvesJYWolfJürgenJRajeNoopur SNSDiamondEli LELHollebecqueAntoineAGervaisRadjRElez-FernandezMaria ElenaMEItalianoAntoineAHofheinzRalf-DieterRDHidalgoManuelMChanEmilyESchulerMartinMLasserreSusan FrancesSFMakrutzkiMartinaMSirzenFlorinFVeroneseMaria LuisaMLTaberneroJosepJBaselgaJoséJengClinicalTrials.govNCT01524978P30 CA008748CANCI NIH HHSUnited StatesClinical Trial, Phase IIJournal ArticleMulticenter StudyResearch Support, Non-U.S. Gov't
United StatesN Engl J Med02555620028-47930Antineoplastic Agents0Indoles0Sulfonamides207SMY3FQTvemurafenibEC Proteins B-rafAIMIMN Engl J Med. 2015 Aug 20;373(8):691-326287847Cancer Discov. 2015 Nov;5(11):111726385779Cancer Discov. 2012 Mar;2(3):227-3522448344N Engl J Med. 2011 Jun 16;364(24):2305-1521663470Blood. 2010 Sep 16;116(11):1919-2320519626Nature. 2002 Jun 27;417(6892):949-5412068308Blood. 2014 Jul 24;124(4):483-9224850756N Engl J Med. 2005 Nov 17;353(20):2135-4716291983J Clin Oncol. 2011 May 20;29(15):2011-921502544N Engl J Med. 2002 Aug 15;347(7):472-8012181401Cell. 2013 Oct 10;155(2):462-7724120142Biometrics. 2004 Jun;60(2):482-9015180674Lancet Oncol. 2012 Mar;13(3):239-4622285168J Clin Oncol. 2000 May;18(10):2095-10310811675Cancer Cell. 2014 Jan 13;25(1):91-10124434212Blood. 2012 Sep 27;120(13):2700-322879539Mod Pathol. 2014 Jul;27(7):1028-3424309328J Clin Oncol. 2000 Jun;18(12):2354-6210856094Eur J Cancer. 2009 Jan;45(2):228-4719097774Lancet Oncol. 2010 Aug;11(8):753-6220619739Cancer Res. 2003 Apr 1;63(7):1454-712670889N Engl J Med. 2011 Jun 30;364(26):2507-1621639808N Engl J Med. 2013 Jun 20;368(25):2385-9423724913N Engl J Med. 2001 Mar 15;344(11):783-9211248153Nat Genet. 2013 Oct;45(10):1113-2024071849JAMA. 2014 May 21;311(19):1998-200624846037Leukemia. 2006 Sep;20(9):1467-7316855634Blood. 2013 Feb 28;121(9):1495-50023258922J Clin Oncol. 2011 Sep 10;29(26):3574-921825258Lancet. 2010 Aug 28;376(9742):687-9720728210Nature. 2012 Jan 26;483(7387):100-322281684N Engl J Med. 2009 Jul 2;361(1):98-919571295AgedAged, 80 and overAntineoplastic Agentsadverse effectstherapeutic useCarcinoma, Non-Small-Cell Lungdrug therapygeneticsDisease-Free SurvivalFemaleHistiocytosisdrug therapygeneticsHumansIndolesadverse effectstherapeutic useLung Neoplasmsdrug therapygeneticsMaleMiddle AgedMutationNeoplasmsdrug therapygeneticsProto-Oncogene Proteins B-rafgeneticsSulfonamidesadverse effectstherapeutic use

Supplemental Content

Loading ...
Support Center